Norchlorcyclizine

Spécifications

303-26-4Numéro CAS

206-137-4Numéro CE

1-[(4-chlorophenyl)-phenylmethyl]piperazineNom IUPAC

C17H19ClN2Formule chimique

286.8 g/molMasse molaire

1-(4-Chlorobenzhydryl)piperazine; 303-26-4; Norchlorcyclizine; N-(p-Chlorobenzhydryl)piperazine; 4-(4-Chlorobenzhydryl)piperazine; N-(4-Chlorobenzhydryl)piperazine; Piperazine, 1-[(4-chlorophenyl)phenylmethyl]-; Piperazine, 1-((4-chlorophenyl)phenylmethyl)-; T875VN0D6E; 1-(4-Chloro-alpha-phenylbenzyl)piperazine; 1-(alpha-Phenyl-4-chlorobenzyl)piperazine; NSC-86164; DTXSID00891490; RefChem:854707; DTXCID70220253; 206-137-4; 1-((4-chlorophenyl)(phenyl)methyl)piperazine; 130018-88-1; 1-[(4-Chlorophenyl)(phenyl)methyl]piperazine; 1-[(4-Chlorophenyl)phenylmethyl]piperazine; 1-[(4-chlorophenyl)-phenylmethyl]piperazine; MFCD00005965; (-)-1-[(4-chlorophenyl) phenylmethyl] piperazine; NSC 86164; C17H19ClN2; 1-(.alpha.-Phenyl-4-chlorobenzyl)piperazine; 1-(4-Chloro-.alpha.-phenylbenzyl)piperazine; 1-[(4-chlorophenyl)-phenyl-methyl]piperazine; (S)-(+)-1-[(4-Chlorophenyl)phenylmethyl]piperazine; 1-((4-chlorophenyl)phenylmethyl)piperazine; Cetirizine EP impurity A; Piperazine, 1-(p-chloro-.alpha.-phenylbenzyl)-; Cetirizine Impurity A; [(4-chlorophenyl)phenylmethyl]piperazine; 1-[(4-chlorophenyl)phenylmethyl)piperazine; Piperazine, 1-(.alpha.-(4-chlorophenyl)benzyl)-; Piperazine, 1-[.alpha.-(4-chlorophenyl)benzyl]-; EINECS 206-137-4; 1-(4-Chlorodiphenylmethyl)piperazine; (R)-(-)-1-[(4-Chlorophenyl)phenylmethyl]piperazine; BRN 0243027; UNII-T875VN0D6E; 4-chlorobenzhydryl piperazine; Piperazine, 1-(alpha-(4-chlorophenyl)benzyl)-; 4-CHLOROBENZHYDRYLPIPERAZINE; 1-(4-Chlorobenzhydryl) piperazine; CBHP; 1-[(R)-(4-chlorophenyl)-phenyl-methyl]piperazine; (S)-Nor-CCZ; Meclozine impurity H CRS; Cetirizine impurity A CRS; Oprea1_771131; 4-23-00-00072 (Beilstein Handbook Reference); MLS000521343; CHEMBL81324; SCHEMBL467086; PIPERAZINE, 1-(p-CHLORO-alpha-PHENYLBENZYL)-; GTPL9162; orb1219348; orb1306637; SCHEMBL1381608; 98% +(contains <7%H2O); GLXC-04310; HMS1648P05; HMS2464F07; NSC86164; NORCHLORCYCLIZINE, (+/-)-; BBL010366; EBC-12607; SBB002998; STK083473; AKOS000268792; AKOS016039386; AC-3019; CS-W001978; FC20350; GF-0133; HY-W001978; SB47944; N-(4-Chlorophenyl)phenylmethylpiperazine; NCGC00245963-01; compound C10 [PMID: 24297249]; SMR000131751; ST042038; SY003580; DB-018556; C1611; EU-0099994; NS00000628; 1-[(4-chlorophenyl)-phenylmethyl]-piperazine; EN300-18220; 1-((4-Chlorophenyl)(phenyl)methyl)-piperazine; N-[(4-chlorophenyl)(phenyl)-methyl]piperazine; T20499; (+/-)-1-(P-CHLOROBENZHYDRYL)PIPERAZINE; (-)-1-[(4chlorophenyl) phenylmethyl]piperazine; 1-[(4-Chloro-phenyl)-phenyl-methyl]-piperazine; CPP_287.1310_14.5; (-)-1-[(4-chloro phenyl)phenylmethyl]piperazine; (RS)-1-[(4-Chlorophenyl)phenylmethyl]piperazine; F068945; SR-01000597190; SR-01000597190-1; (-)-1-[(4-Chloro-phenyl)-phenyl-methyl]-piperazine; Q27076864; Z57388987; 1-(4-Chlorobenzhydryl)piperazine, technical grade, 90%; USP CBHP; 1-((4-chlorophenyl)(phenyl)methyl)piperazine; CETIRIZINE DIHYDROCHLORIDE IMPURITY A [EP IMPURITY]; HYDROXYZINE HYDROCHLORIDE IMPURITY A [EP IMPURITY]; MECLOZINE DIHYDROCHLORIDE IMPURITY H [EP IMPURITY]; CETIRIZINE HYDROCHLORIDE IMPURITY CBHP [USP IMPURITY]; Meclozine impurity H, European Pharmacopoeia (EP) Reference Standard; Cetirizine impurity A, European Pharmacopoeia (EP) Reference Standard; Cetirizine EP Impurity A; Hydroxyzine EP Impurity A; Meclozine EP Impurity HSynonymes